Have you finally decided to explore treatment plans for weight loss or erectile dysfunction? Are you finding that ...

New research shows that Ozempic and similar drugs reduce opioid overdoses by 40% and alcohol intoxication by 50% in people ...

The FDA clarified Thursday that it won't take action against GLP-1 compounders for certain violations while it reevaluates ...

Only 15% of those who start a glucagon-like peptide 1 (GLP-1) for weight loss are still taking it two years according to ...

The use of GLP-1 RAs is associated with the risk for retained gastric contents and inadequate bowel preparation during endoscopic procedures.

U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, ...

Since 2021, the Obesity Action Coalition (OAC) has led a national public awareness campaign against weight bias with a goal ...

A review of the medical records of thousands of adolescents treated for obesity found that kids who received the GLP-1 medications semaglutide or liraglutide were less likely to ...

The New York Times: Ozempic's Next Magic Trick: Treating Drug Addiction Could these medications — collectively known as GLP-1 receptor agonists — also fight America’s most difficult drug ...

A large study of veterans with type 2 diabetes finds better short-term kidney outcomes with use of SGLT2 inhibitors vs GLP-1 receptor agonists.

The discovery of a gut-to-brain regulation pathway in flies calls for additional consideration on how certain medications, especially GLP-1 agonists, can be used to treat obesity and diabetes in ...

GLP-1 receptor agonists and similar drugs may protect people with opioid or alcohol use disorder from opioid overdose and ...